Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial
about
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibilityMultiple versus one or more antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attackDipyridamole for preventing stroke and other vascular events in patients with vascular diseaseEffects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second StrokesAspirin and extended-release dipyridamole versus clopidogrel for recurrent strokeAngioplasty and stenting for atherosclerotic intracranial stenosis: rationale for a randomized clinical trialUric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?Secondary stroke prevention: challenges and solutionsTIA Management: Should TIA Patients be Admitted? Should TIA Patients Get Combination Antiplatelet Therapy?Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-AnalysisAntiplatelet therapy for carotid artery stentingAnti-platelet therapy: phosphodiesterase inhibitors.Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysisAntithrombotic treatment for peripheral arterial diseaseEvolving perspectives on clopidogrel in the treatment of ischemic strokeRationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patientThe PRoFESS trial: future impact on secondary stroke preventionSecondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?Update on the use of antiplatelet agents in secondary stroke preventionDipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIAThe neuron-astrocyte-microglia triad in a rat model of chronic cerebral hypoperfusion: protective effect of dipyridamole.Individual patient data meta-analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and design.Utility of electronic patient records in primary care for stroke secondary prevention trials.Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.Program of rehabilitative exercise and education to avert vascular events after non-disabling stroke or transient ischemic attack (PREVENT Trial): a multi-centred, randomised controlled trialRemote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic AttackDual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and consInclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease.Preventing recurrent cerebrovascular events in patients with stroke or transient ischemic attack: the current data.Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses.Evidence-based management of carotid artery diseasePredictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial.Transient ischaemic attack (TIA) knowledge in general practice: a cross-sectional study of Western Adelaide general practitionersUpdate to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic strokeOral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in elderly people in Poland.Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management.Dual antiplatelet therapy in secondary prevention of ischemic stroke: a ghost from the past or a new frontier?Secondary prevention after minor stroke and TIA - usual care and development of a support programIntensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): a protocol for a randomised controlled trial.
P2860
Q21144269-C2738439-8ACA-4277-BFF0-01A46518373AQ24201386-EABC7D27-AE77-4CBF-8865-A9854898CE25Q24243858-9D3B0845-28C7-447A-8288-2B030E160A92Q24645205-9A17B557-C93B-428C-BA2D-1442764C4580Q24646522-3D72DD61-60B2-41A3-8F7B-DDAA6154E344Q24676024-2806A9B1-6CF1-4B85-A7AC-D33619592041Q24678615-8C9AB55A-7E89-4AFF-8ECA-09EFCF7D8AA9Q26795568-F63F5A9B-699C-4C18-AC03-C230F931C616Q26796466-05C66E3C-E93F-43A7-B080-54BD69CA7F11Q26797510-D12D1A2E-AC4C-4D30-9FA9-CDAC57B39167Q26852304-EE04CDDC-6B8B-4F04-A718-5A0604E8F6D5Q27687228-F145A394-A84F-4D47-8D3C-96DEC792AE3BQ28076042-0400C452-9C5D-41F3-976A-A1A455FE95B8Q28200650-27FC5841-8A57-4D5E-8821-FCA36DF75AF2Q28217627-2CC786E5-979C-4AD7-B493-3568A5C1FE00Q28219951-16244920-A638-4CA7-B332-5756B7339D9CQ28221589-3DF58CDE-1080-47EE-A1FA-AD072D7ECF87Q28221595-EF6DC7A0-1D8C-4C78-8EE9-7D4AEFCBB21DQ28221822-918DFFA9-E770-4E13-8E4E-489F3F9341B7Q28222567-570AEC60-F759-4307-BD22-00E2BC2AA13CQ30602337-9D4718BB-42D0-40CA-9902-FA07D1ECF896Q30987806-42E9E0C0-F18D-4E07-A2E2-B6F8DB879625Q30998805-6382B2CA-AA0F-46BD-8749-BB65875E37BEQ33390176-577F2599-4337-4EF1-8751-2C4F361C7A73Q33766889-ACD6A1DD-F77D-4979-A735-615A6A1F8CC4Q33775718-60E08BFF-0270-4C26-99D1-FF3A0D8525FAQ33911647-C7E4F8F7-F73E-4A86-AEBC-0CEDDE497C9BQ34010411-76703331-5FE0-4991-B63D-4B8FE83EE362Q34092629-EF4BE2CC-75FA-43C0-A5AF-6D9EE65E4524Q34134653-F4EBAF76-E5E7-4AF6-9360-A77C4E411ECEQ34175306-A0073F5C-926C-4C26-8C57-CE8149BE6187Q34244196-AA4CA09E-A7FF-4AA6-A342-7BE84CC9506AQ34296397-3B1D253F-3AD0-4764-A6A7-C36DF71BA6F1Q34344580-3CEB74ED-D3AF-4F32-91E7-D92F0631DEE2Q34367350-E9818E66-AE13-4739-BE48-8C4595A34A81Q34462760-E80E0BEF-9F05-4DE6-8146-211266C18BA5Q34476952-EB76F264-BABE-416A-8569-165D25257EBCQ34479105-8DE4ED34-4868-4336-9FF0-2216C2C9A29FQ34531505-8498976B-A906-4D1C-88CD-E587A84C8437Q34561255-F4BB9370-B62C-4ACA-BB29-60FD95C31C3A
P2860
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@ast
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@en
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@nl
type
label
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@ast
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@en
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@nl
prefLabel
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@ast
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@en
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@nl
P2093
P1433
P1476
Aspirin plus dipyridamole vers ...... ): randomised controlled trial
@en
P2093
J van Gijn
L J Kappelle
P H A Halkes
P J Koudstaal
P304
P356
10.1016/S0140-6736(06)68734-5
P407
P577
2006-05-20T00:00:00Z